HY-122331-100mg
|
MedChemexpress LLC
|
Norbormide [CAS 991-42-4]
|
|
|
|
HY-P80958-10uL
|
MedChemexpress LLC
|
SATB2 Antibody
|
|
|
|
HY-P80958-100uL
|
MedChemexpress LLC
|
SATB2 Antibody
|
|
|
|
HY-P80958-50uL
|
MedChemexpress LLC
|
SATB2 Antibody
|
|
|
|
HY-P99271-1mg
|
MedChemexpress LLC
|
Tisotumab [CAS 1418628-81-5]
|
|
Cancer-programmed cell death
|
|
HY-P99271-10mg
|
MedChemexpress LLC
|
Tisotumab [CAS 1418628-81-5]
|
|
Cancer-programmed cell death
|
|
HY-P99271-5mg
|
MedChemexpress LLC
|
Tisotumab [CAS 1418628-81-5]
|
|
Cancer-programmed cell death
|
|
HY-152963-1mg
|
MedChemexpress LLC
|
Tisotumab vedotin [CAS 1418731-10-8]
|
|
Cancer-programmed cell death
|
|
HY-152963-5mg
|
MedChemexpress LLC
|
Tisotumab vedotin [CAS 1418731-10-8]
|
|
Cancer-programmed cell death
|
|
HY-P73594-10ug
|
MedChemexpress LLC
|
Tissue Factor, Rabbit (HEK293, His)
|
|
|
|
HY-P73594-100ug
|
MedChemexpress LLC
|
Tissue Factor, Rabbit (HEK293, His)
|
|
|
|
HY-P73594-5ug
|
MedChemexpress LLC
|
Tissue Factor, Rabbit (HEK293, His)
|
|
|
|
HY-P73594-50ug
|
MedChemexpress LLC
|
Tissue Factor, Rabbit (HEK293, His)
|
|
|
|
HY-P99336-1mg
|
MedChemexpress LLC
|
Enlimomab [CAS 142864-19-5]
|
|
COVID-19-immunoregulation
|
|
HY-P99336-10mg
|
MedChemexpress LLC
|
Enlimomab [CAS 142864-19-5]
|
|
COVID-19-immunoregulation
|
|
HY-P99336-5mg
|
MedChemexpress LLC
|
Enlimomab [CAS 142864-19-5]
|
|
COVID-19-immunoregulation
|
|
HY-P80970-10uL
|
MedChemexpress LLC
|
FMRP Antibody
|
|
|
|
HY-P80970-100uL
|
MedChemexpress LLC
|
FMRP Antibody
|
|
|
|
HY-P80970-50uL
|
MedChemexpress LLC
|
FMRP Antibody
|
|
|
|
HY-N2503-1mg
|
MedChemexpress LLC
|
Ginsenoside F4 [CAS 181225-33-2]
|
|
COVID-19-immunoregulation
|
|
HY-N2503-5mg
|
MedChemexpress LLC
|
Ginsenoside F4 [CAS 181225-33-2]
|
|
COVID-19-immunoregulation
|
|
HY-P99673-1mg
|
MedChemexpress LLC
|
Itepekimab [CAS 2226742-52-3]
|
|
COVID-19-immunoregulation
|
|
HY-P99673-10mg
|
MedChemexpress LLC
|
Itepekimab [CAS 2226742-52-3]
|
|
COVID-19-immunoregulation
|
|
HY-P99673-5mg
|
MedChemexpress LLC
|
Itepekimab [CAS 2226742-52-3]
|
|
COVID-19-immunoregulation
|
|